Prostate cancer testing is on trial

June 3, 2014, University of Sydney
Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

(Medical Xpress)—The University of Sydney's School of Public Health is seeking people to participate in a "community jury" to independently asses the process of Prostate Specific Antigen (PSA) testing in Australia.

The PSA test is often used to test healthy men to see whether they have prostate cancer. However, experts disagree about whether, when and how the PSA test should be used for this purpose.

Chief investigator of the study, Associate Professor Stacy Carter, said this study is important because although many men are concerned about prostate cancer, the messages they receive can be confusing.

"Our research team is calling out for participants to be part of a community jury to consider how men and their GPs should approach PSA testing," she said.

"We will present the current evidence and then ask people to consider, debate and decide the best way to manage PSA testing for prostate cancer in otherwise healthy men.

"Those arguing for the PSA test say it can save men's lives and may prevent problems from development of primary and secondary tumours. Those arguing against it say it leads to many men being unnecessarily harmed.

"Because of this genuine disagreement over the merits of the PSA, men and their GPs are in a difficult position when trying to decide what to do."

The PSA test measures the blood level of PSA, a protein that is produced by the . Although a higher PSA level may indicate a higher risk of prostate cancer, there are other, non-cancer related reasons for having an elevated PSA level. And some men who have prostate cancer do not have elevated PSA.

"Prostate cancer is a fatal disease for a minority of men and the PSA test is intended to identify the cancer early so that it can be treated and prevent life-threatening disease," Associate Professor Carter said.

"But there is a disagreement about whether screening is beneficial as many men can have prostate cancer diagnosed but not experience physical symptoms or difficulties. This means detecting prostate cancer early will not necessarily reduce the chance of dying from prostate cancer.

"The concern about the PSA is that the test can provide false positive results, as well as false negative results. It can also lead to over-diagnosis (detecting tumours that aren't life threatening) and over-treatment (treating tumours that aren't life threatening).

"Overtreatment exposes men unnecessarily to the potential complications and harmful side effects of treatments for early , including surgery and radiation therapy. The side effects of these treatments can include urinary incontinence, problems with bowel function, and erectile dysfunction.

"This project aims to answer what the moral obligations of GPs are in respect to PSA testing, and what should constitute informed consent to perform a PSA test.

"We are recruiting participants for a series of community juries to consider this problem. A community jury is like a jury in a court room. Expert witnesses present evidence and information, and then the jury debates and comes to a conclusion.

"We are keen to involve all sorts of people of voting age: older and younger, and women.

"We will be running four separate juries, in July, August and October at the University of Sydney in Camperdown. Research has shown that people who participate in a community jury find it a highly rewarding experience," Associate Professor Carter said.

This project is part of a larger study examining the role of values, ethics, and evidence in cancer screening policy and practice. It is a collaborative initiative involving academics from the University of Sydney's School of Public Health, Centre for Values, Ethics and the Law in Medicine, University of Notre Dame's School of Medicine, Cancer Council Australia, and the SAX Institute.

Explore further: Organized screening for prostate cancer does more harm than good

Related Stories

Organized screening for prostate cancer does more harm than good

September 30, 2013
Prostate cancer screening using the prostate-specific antigen (PSA) test is widely used in France despite a lack of evidence showing that it reduces cancer deaths. Now, researchers have shown that men experience more harm ...

PSA-testing and early treatment decreases risk of prostate cancer death

March 10, 2014
Mortality in prostate cancer is lower in areas with frequent use of PSA testing compared with areas with little testing shows a study published online today in Journal of the National Cancer Institute by researchers from ...

PSA test for men could get a second life for breast cancer in women

July 13, 2011
The widely known PSA blood test for prostate cancer in men may get a second life as a much-needed new test for breast cancer, the most common form of cancer in women worldwide, scientists are reporting in a new study in the ...

Chronic inflammation linked to 'high-grade' prostate cancer

April 18, 2014
Men who show signs of chronic inflammation in non-cancerous prostate tissue may have nearly twice the risk of actually having prostate cancer than those with no inflammation, according to results of a new study led by researchers ...

New early detection test for prostate cancer: Mi-Prostate Score test improves on PSA for predicting cancer

September 26, 2013
More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a cancer diagnosis.

Digital rectal exam remains important part of prostate screening

March 18, 2013
(Medical Xpress)—The digital rectal exam is an important screening test that can discover prostate cancer that a prostate-specific antigen or PSA test may not, despite the higher sensitivity of the PSA test, according to ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.